Navigation Links
invivodata Announces ePROficiency 2009 Web Seminar Series

Five Complimentary Webinars to Showcase Case Studies and Patient Reported Outcome Strategies

PITTSBURGH, June 9 /PRNewswire/ -- invivodata inc., the industry leader in electronic patient reported outcomes (ePRO) solutions and services for global clinical research, today announced its 2009 ePROficiency(TM) Web seminar series on Patient Reported Outcomes (PRO).

The webinar series is a continuation of invivodata's educational initiative which focuses on recent regulatory and industry trends related to PROs. Each of the series' five webinars is derived from presentations that were delivered by industry experts during invivodata's recently concluded ePROficiency Conference in Naples, FL.

Each complimentary webinar will feature international pharmaceutical researchers delivering insight on specific aspects of PRO in clinical research and answering questions on topics including:

  • Improving Measure Sensitivity in Early Stage Research - June 18
  • A Conceptual Model in the Context of a Global Drug Development Program - July 30
  • Developing PROs: Common Pitfalls & Recent Experiences - September 10
  • Supporting Regulatory Submissions and Inspections: the ePRO Perspective - October 22
  • eDiaries: From Clinical Proof-of-Concept through to NDA Approval - December 3

"We've always been very pleased with the response to our webinar programs, which represents the growing interest we've seen in PROs for clinical research," said Dr. Jean Paty, chief scientist and regulatory advisor at invivodata's consulting division, PRO Consulting(R). Considering the evolving use of PROs and its regulatory implications, it's no surprise that so many global trial sponsors are eager to learn more about the latest PRO strategies and trends."

To register for any of the webinars or to see a complete schedule of upcoming invivodata events, please visit

About invivodata inc.

invivodata combines behavioral science, information technology, and clinical research expertise to capture high quality clinical trial data directly from patients. invivodata's electronic Patient Reported Outcomes (ePRO) solutions, which are based on over 20 years of research, deliver reliable patient self-reported data by driving patient compliance with the protocol and eliminating recall biases that plague paper-based self-report data. invivodata's solutions include comprehensive trial-support services that facilitate the collection of ePRO data, web-based access to study data and operational reports that give researchers and sponsors visibility into study progress, and scientific and regulatory consulting on the use of PRO data in a regulated environment. invivodata's solution has been used in more than 275 clinical programs and is the industry-leading ePRO system in delivering primary efficacy data for FDA drug approvals. invivodata inc. is a privately held company with global headquarters in Pittsburgh, Pa., USA; its European headquarters is in London, England; and its technology development center is in Scotts Valley, Calif., USA. For more information visit

    For more information, contact:

    invivodata inc.
    Christine Tobin
    Corporate Communications Specialist
    (412) 390-3000, ext. 3502

SOURCE invivodata inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. invivodata and PRO Consulting to Present at International Industry Events
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... published their findings on what they believe could be a new and helpful ... the new research. Click here to read it now. , Biomarkers ...
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
Breaking Biology Technology:
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
Breaking Biology News(10 mins):